Additive antiangiogenesis effect of ginsenoside Rg3 with low-dose metronomic temozolomide on rat glioma cells both in vivo and in vitro

BACKGROUND: Glioblastoma is the most common and deadly primary brain tumor in adults. Low-dose,metronomic (LDM) temozolomide (TMZ) displays improved efficacy in the treatment of glioblastoma by targeting angiogenesis, but has a limited effect on recurrence. The antiangiogenesis drug ginsenoside Rg3...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Caixing, Yu, Yang, Wang, Lizhen, Wu, Bin, Xia, Liang, Feng, Fang, Ling, Zhiqiang, Wang, Shihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752767/
https://www.ncbi.nlm.nih.gov/pubmed/26872471
http://dx.doi.org/10.1186/s13046-015-0274-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752767/
https://www.ncbi.nlm.nih.gov/pubmed/26872471
http://dx.doi.org/10.1186/s13046-015-0274-y

Ejemplares similares